000			01852nam a2200265 4500
001			ESSALUD
005			20260902145412.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aAronson, Naomi E. _eAutor _954420
245			_aLeishmaniasis
300			_apáginas: 2026-2039
520			_aLeishmaniases comprise clinically distinct diseases caused by the protozoan parasite leishmania, which is transmitted through the bite of infected sand flies. Cutaneous leishmaniasis is the most common form and manifests as a localized skin lesion. Mucosal leishmaniasis causes destructive nose, mouth, and throat lesions. Visceral leishmaniasis is a potentially life-threatening form that results from bloodborne dissemination of the parasites. The number of cases of cutaneous leishmaniasis is increasing, particularly in the Eastern Mediterranean region, and the prevalence of visceral leishmaniasis is decreasing globally. Laboratory diagnosis of the leishmaniases has shifted to the use of molecular methods to test tissue samples (e.g., skin or bone marrow), which can be used to identify infecting species. Treatment is challenged by limited drug choices. A recent advance is the use of combination therapies for visceral leishmaniasis. Two human leishmaniasis vaccines are undergoing preclinical testing or are ready for human testing.
650			_aSALUD GLOBAL _910472
650			_aENFERMEDADES INFECCIOSAS GENERALES _954087
650			_aINFECCIONES PARASITARIAS _954373
650			_aSALUD PÚBLICA GENERAL _954132
650			_aVACUNAS _98158
700			_aMusa, Ahmed M. _954421
700			_aSatoskar, Abhay R. _954422
773	0		_022717 _922665 _dMassachusetts NEJM Group _oNEJM013 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-28 _zsqb
999			_c22889 _d22889